Borderline Resectable Pancreatic Cancer
📧 Sign up to get email alerts when something new happens for Borderline Resectable Pancreatic Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer [Phase 2]
Phase 2 clinical trial investigating neoadjuvant therapy with gemcitabine, nab-paclitaxel, durvalumab, and oleclumab for resectable or borde…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer [Phase 1]
Phase 1 trial of NBTXR3 activated by radiation therapy for borderline resectable or locally advanced pancreatic cancer has been suspended.
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) [Phase 1, Phase 2]
An update on a Phase 1/Phase 2 trial evaluating neoadjuvant TAMP (PRISM-TAMP) for pancreatic ductal adenocarcinoma, with attention to tumor …
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
A planned clinical trial uses endoscopic ultrasound-guided circulating tumor cells combined with multi-omics to predict recurrence and metas…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer [Phase 2]
A Phase 2 clinical trial is evaluating IBI343 in combination with chemotherapy as neoadjuvant therapy for borderline resectable pancreatic c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating zimberelimab and quemliclustat with chemotherapy for borderline resectable or locally advanced pancreati…
-
CLINICAL_TRIALS other · 2026-01-12Clinical Trial Update: Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer [NA]
Clinical trial status update indicating a study evaluating chemotherapy with or without IMD10 (focused ultrasound) for border-line resectabl…
-
CLINICAL_TRIALS research · 2025-04-25Clinical Trial Update: A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer
This clinical trial outlines a personalized management pathway for locally advanced and borderline resectable pancreatic cancer and is curre…
-
CLINICAL_TRIALS research · 2025-04-02Clinical Trial Update: Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial) [NA]
The PeRFormanCe trial is exploring diffusion-weighted MRI, radiomics, and liquid biopsy to predict surgical resectability after FOLFIRINOX i…
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer [Phase 2]
A Phase 2 trial evaluating GVAX Pancreas Vaccine with cyclophosphamide in combination with nivolumab and SBRT for borderline resectable panc…
-
CLINICAL_TRIALS trial_result · 2024-08-09Clinical Trial Update: Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer [EARLY_Phase 1]
This early phase 1 trial evaluates nivolumab in combination with chemotherapy before surgery in patients with borderline resectable pancreat…
-
CLINICAL_TRIALS research · 2024-07-10Clinical Trial Update: Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer [Phase 2]
A Phase 2 clinical trial evaluating irinotecan liposome II in combination with 5-FU/leucovorin and oxaliplatin for perioperative treatment o…
-
CLINICAL_TRIALS trial_result · 2024-05-21Clinical Trial Update: Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer [Phase 2]
A Phase 2b trial evaluating GC4711 in combination with SBRT for nonmetastatic pancreatic cancer was terminated, with results posted in May 2…
-
CLINICAL_TRIALS trial_result · 2024-05-07Clinical Trial Update: IORT on Borderline Resectable Pancreatic Cancer [Phase 2]
Phase 2 clinical trial evaluating intraoperative radiation therapy (IORT) for borderline resectable pancreatic cancer has been suspended.
-
CLINICAL_TRIALS trial_result · 2024-04-03Clinical Trial Update: NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study [Phase 2]
Phase 2 exploratory trial evaluating NALIRIFOX in combination with camrelizumab for borderline resectable pancreatic cancer.
-
CLINICAL_TRIALS trial_result · 2022-01-28Clinical Trial Update: AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer [Phase 3]
A Phase 3 trial comparing AG versus mFOLFIRINOX as neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer.
-
CLINICAL_TRIALS trial_result · 2020-09-10Clinical Trial Update: Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer [Phase 2]
Phase 2 trial investigating neoadjuvant FOLFIRINOX or nab-paclitaxel with gemcitabine for borderline resectable pancreatic cancer.
-
CLINICAL_TRIALS trial_result · 2020-03-10Clinical Trial Update: Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer [Phase 2]
Phase 2 trial update investigating neoadjuvant nab-paclitaxel and S-1 in borderline resectable pancreatic cancer.